Format

Send to

Choose Destination
Br J Radiol. 2016 Jun;89(1062):20150824. doi: 10.1259/bjr.20150824. Epub 2016 Mar 17.

Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer.

Author information

1
1 Department of Radiation Oncology, Hospital de la Vall d'Hebron, Barcelona, Spain.
2
2 Department of Medical Physics, Hospital de la Vall d'Hebron, Barcelona, Spain.
3
3 Department of Radiology, Hospital de la Vall d'Hebron, Barcelona, Spain.
4
4 Department of Nuclear Medicine, Hospital de la Vall d'Hebron, Barcelona, Spain.

Abstract

OBJECTIVE:

This study assessed the toxicity and clinical outcomes of three-dimensional (3D) hypofractionated radiotherapy (HFRT) for medically inoperable T1-3 N0-1 non-small-cell lung cancer (NSCLC).

METHODS:

34 patients with inoperable early-stage NSCLC were treated from August 2008 to April 2013. Prior to enrolment, patients were required to be evaluated by an experienced thoracic surgeon to determine the "operability". All received 57 Gy in 19 fractions followed by escalated doses of 3-Gy fractions, up to a total dose of 66 Gy using a 3D conformal technique. Toxicities were measured using the Common Terminology Criteria for Adverse Effects v. 4.0.

RESULTS:

The median follow-up was 33 months (7-74 months). Toxicity grades ≥3 were not observed. Local control (LC) was 80.4% at 2 years, whereas regional control (RC) was 78%. The overall survival (OS), time to progression (TTP) and time to distant metastasis (TTM) at 2 years were 60%, 59% and 80%, respectively. For patients with T1-2 N0 and a tumour size <45 mm (n = 19), rates of OS, TTP and TTM at 2 years were 71%, 75% and 94%, respectively. LC and RC at 2 years were 85% and 94%, respectively.

CONCLUSION:

HFRT using 3.0-Gy fractions amounting to a total dose of 66 Gy is the recommended dose. A Phase 2 trial is warranted in order to assess the safety and efficacy of this fractionation scheme.

ADVANCES IN KNOWLEDGE:

HFRT results in a favourable outcome in early-stage lung cancer without the usual restrictions in tumour size and/or location associated with previous treatment methods. No special equipment is required, therefore permitting its application in any centre.

PMID:
26986457
PMCID:
PMC5258152
DOI:
10.1259/bjr.20150824
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center